Top-Rated StocksTop-RatedNASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis → America could fall from this event (From Porter & Company) (Ad) Free ITCI Stock Alerts $65.71 -0.61 (-0.92%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$65.17▼$67.2750-Day Range$64.37▼$79.8452-Week Range$45.50▼$84.89Volume696,954 shsAverage Volume925,453 shsMarket Capitalization$6.94 billionP/E RatioN/ADividend YieldN/APrice Target$90.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside37.2% Upside$90.17 Price TargetShort InterestHealthy3.48% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.84Based on 21 Articles This WeekInsider TradingSelling Shares$11.36 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.52) to $0.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.82 out of 5 starsMedical Sector150th out of 2,771 stocksPharmaceutical Preparations Industry56th out of 1,288 stocks 4.5 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intra-Cellular Therapies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.48% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 2.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 3.8 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Intra-Cellular Therapies this week, compared to 5 articles on an average week.Search Interest5 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows44 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 529% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,364,950.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intra-Cellular Therapies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.52) to $0.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -56.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -56.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Intra-Cellular Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesMay 13 at 4:25 AM | americanbankingnews.comCantor Fitzgerald Brokers Increase Earnings Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)May 11 at 2:13 AM | americanbankingnews.comLeerink Partnrs Brokers Boost Earnings Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)May 10, 2024 | markets.businessinsider.comMaintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study OutlookMay 10, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. Forecasted to Post FY2025 Earnings of $1.50 Per Share (NASDAQ:ITCI)May 9, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call TranscriptMay 8, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Given Buy Rating at Needham & Company LLCMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...May 7, 2024 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations with Caplyta Sales SurgeMay 7, 2024 | msn.comITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comIntra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA SalesMay 7, 2024 | msn.comIntra-Cellular Therapies beats Q1 estimatesMay 7, 2024 | globenewswire.comIntra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 5, 2024 | americanbankingnews.comIntra-Cellular Therapies (ITCI) to Release Earnings on TuesdayApril 30, 2024 | globenewswire.comIntra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and WebcastApril 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)April 24, 2024 | finance.yahoo.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApril 24, 2024 | globenewswire.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesApril 24, 2024 | investorplace.com3 Biotech Stocks With Skyrocketing Potential: April 2024April 22, 2024 | msn.comIpsen, Skyhawk enter RNA targeting research collab in rare neurological diseasesApril 20, 2024 | money.usnews.comIntra-Cellular Therapies IncApril 17, 2024 | globenewswire.comIntra-Cellular Therapies Prices Public Offering of Common StockApril 17, 2024 | investors.comBiotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy PointApril 17, 2024 | finance.yahoo.comIntra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?See More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$90.17 High Stock Price Target$120.00 Low Stock Price Target$62.00 Potential Upside/Downside+37.2%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-21.57% Pretax Margin-21.38% Return on Equity-18.49% Return on Assets-15.26% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio5.00 Sales & Book Value Annual Sales$464.37 million Price / Sales14.94 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book10.68Miscellaneous Outstanding Shares105,570,000Free Float101,985,000Market Cap$6.94 billion OptionableOptionable Beta1.01 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Comp: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZCytokineticsNASDAQ:CYTKElanco Animal HealthNYSE:ELANBlueprint MedicinesNASDAQ:BPMCCerevel TherapeuticsNASDAQ:CEREView All CompetitorsInsiders & InstitutionsAmerican International Group Inc.Sold 396 shares on 5/14/2024Ownership: 0.044%CANADA LIFE ASSURANCE CoBought 8,760 shares on 5/14/2024Ownership: 0.016%NatixisBought 2,329 shares on 5/14/2024Ownership: 0.004%EntryPoint Capital LLCBought 1,259 shares on 5/14/2024Ownership: 0.002%HAP Trading LLCBought 35,000 shares on 5/13/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price target for 2024? 10 Wall Street research analysts have issued 1-year target prices for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $120.00. On average, they anticipate the company's stock price to reach $90.17 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2024? Intra-Cellular Therapies' stock was trading at $71.62 at the start of the year. Since then, ITCI shares have decreased by 8.3% and is now trading at $65.71. View the best growth stocks for 2024 here. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. The biopharmaceutical company had revenue of $144.90 million for the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative trailing twelve-month return on equity of 18.49%. Intra-Cellular Therapies's revenue was up 52.0% compared to the same quarter last year. During the same period last year, the company posted ($0.46) EPS. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Psychedelics ETF (PSIL), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), iShares U.S. Pharmaceuticals ETF (IHE) and Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.53%), Wasatch Advisors LP (3.98%), Clearbridge Investments LLC (1.65%), Assenagon Asset Management S.A. (0.67%), Principal Financial Group Inc. (0.54%) and Lord Abbett & CO. LLC (0.49%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITCI) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.